The burden of undertreatment and non-treatment among patients with non-valvular atrial fibrillation and elevated stroke risk: a systematic review

References

• Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112(8):1142–1147.
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the AnTicoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285(18):2370.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a Report From the American Heart Association. Circulation. 2019;139(10):e56–e528.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Underlying cause of death, 1999–2018. 2020. [cited 2020 Mar 12]. https://wonder.cdc.gov/controller/datarequest/D76.
   Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration with the Society of THORACIC surgeons. Circulation. 2019;140(2):e125–e151.
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22(8):983–988.
   PubMed Web of Science ®Google Scholar
• Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498.
   PubMed Web of Science ®Google Scholar
• Joung B, Lee JM, Lee KH, et al. 2018 Korean guideline of atrial fibrillation management. Korean Circ J. 2018;48(12):1033–1080.
   PubMed Web of Science ®Google Scholar
• Brieger D, Amerena J, Attia JR, et al. National heart foundation of Australia and cardiac society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. Med J Aust. 2018;209(8):356–362.
   PubMed Web of Science ®Google Scholar
• Group JJW. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013)–digest version. Circ J. 2014;78(8):1997–2021.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199–e267. 2014
   PubMed Web of Science ®Google Scholar
• Amin A. Oral anticoagulation to reduce risk of stroke in patients with atrial fibrillation: current and future therapies. Clin Interv Aging. 2013;8:75–84.
   PubMed Web of Science ®Google Scholar
• Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154(13):1449–1457.
   PubMed Web of Science ®Google Scholar
• Food & Drug Administration. Pradaxa Highlights of Prescribing Information. 2010. [cited 2020 Jul 16]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022512s000lbl.pdf.
   Google Scholar
• Food & Drug Administration. Xarelto highlights of prescribing information. 2012. [cited 2020 Jul 16]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022406s001s002s003lbl.pdf.
   Google Scholar
• Food & Drug Administration. Eliquis highlights of prescribing information. 2012. [cited 2020 Jul 16]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf.
   Google Scholar
• Food & Drug Administration. Savaysa highlights of prescribing information. 2015. [cited 2020 Jul 16]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf.
   Google Scholar
• Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–817.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Investigators: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Chan PS, Maddox TM, Tang F, et al. Practice-Level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program). Am J Cardiol. 2011;108(8):1136–1140.
   PubMed Web of Science ®Google Scholar
• Verdino RJ. Untreated atrial fibrillation in the United States of America: understanding the barriers and treatment options. J Saudi Heart Assoc. 2015;27(1):44–49.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Stroke facts. 2017.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097
   PubMed Web of Science ®Google Scholar
• Fuster V, Rydén LE, Cannom DS, et al. ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the heart rhythm society. J Am Coll Cardiol. 2011;57(11):e101–e198.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs. [cited 2020 Oct 21]. https://www.accessdata.fda.gov/scripts/cder/daf/.
   Google Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: University of Ottawa; 2000.
   Google Scholar
• Frewen J, Finucane C, Cronin H, et al. Factors that influence awareness and treatment of atrial fibrillation in older adults. QJM Int J Med. 2013;106(5):415–424.
   PubMed Web of Science ®Google Scholar
• Casciano JP, Dotiwala ZJ, Martin BC, et al. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective. J Manag Care Pharm. 2013;19(4):302–316.
   PubMed Web of Science ®Google Scholar
• Hess PL, Kim S, Fonarow GC, et al. Absence of oral anticoagulation and subsequent outcomes among outpatients with atrial fibrillation. Am J Med. 2017;130(4):449–456.
   PubMed Web of Science ®Google Scholar
• LaMori JC, Mody SH, Gross HJ, et al. Burden of comorbidities among patients with atrial fibrillation. Ther Adv Cardiovasc Dis. 2013;7(2):53–62.
   PubMedGoogle Scholar
• Piccini JP, Mi X, DeWald TA, et al. Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. Heart Rhythm. 2012;9(9):1403–1408.
   PubMed Web of Science ®Google Scholar
• Hsu JC, Maddox TM, Kennedy K, et al. Aspirin instead of oral anticoagulant prescription in atrial fibrillation patients at risk for stroke. J Am Coll Cardiol. 2016;67(25):2913–2923.
   PubMed Web of Science ®Google Scholar
• Hsu JC, Maddox TM, Kennedy KF, et al. Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: Insights from the NCDR PINNACLE registry. JAMA Cardiol. 2016;1(1):55–62.
   PubMed Web of Science ®Google Scholar
• Marzec LN, Wang J, Shah ND, et al. Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation. J Am Coll Cardiol. 2017;69(20):2475–2484.
   PubMed Web of Science ®Google Scholar
• Apenteng PN, Gao H, Hobbs FR, et al. Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry. BMJ Open. 2018;8(1):e018905.
   PubMed Web of Science ®Google Scholar
• Holt TA, Hunter TD, Gunnarsson C, et al. Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey. Br J Gen Pract. 2012;62(603):e710–e717.
   PubMed Web of Science ®Google Scholar
• Huisman MV, Rothman KJ, Paquette M, et al. The changing landscape for stroke prevention in AF: findings from the GLORIA-AF Registry Phase 2. J Am Coll Cardiol. 2017;69(7):777–785.
   PubMed Web of Science ®Google Scholar
• de Andrés-Nogales F, Oyagüez I, Betegón-Nicolás L, et al. Status of oral anticoagulant treatment in patients with nonvalvular atrial fibrillation in Spain. REACT-AF Study. Rev Clin Esp. 2015;215(2):73–82.
   PubMed Web of Science ®Google Scholar
• Jolliffe E, Fu V, Lanford J, et al. Burden of atrial fibrillation: a retrospective review of patients presenting to acute medical services. Intern Med J. 2016;46(10):1166–1171.
   PubMed Web of Science ®Google Scholar
• Proietti M, Laroche C, Opolski G, et al. 'Real-world' atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase. Europace. 2017;19(5):722–733. euw112.
   PubMed Web of Science ®Google Scholar
• Son MK, Lim N-K, Kim HW, et al. Risk of ischemic stroke after atrial fibrillation diagnosis: a national sample cohort. Bishopric NH, ed. PLoS One. 2017;12(6):e0179687.
   PubMed Web of Science ®Google Scholar
• Inoue H, Atarashi H, Okumura K, et al. Impact of gender on the prognosis of patients with nonvalvular atrial fibrillation. Am J Cardiol. 2014;113(6):957–962.
   PubMed Web of Science ®Google Scholar
• Martin AL, Reeves AG, Berger SE, et al. Systematic review of societal costs associated with stroke, bleeding and monitoring in atrial fibrillation. J Comp Eff Res. 2019;8(14):1147–1166.
   PubMed Web of Science ®Google Scholar
• Amin A, Keshishian A, Xie L, et al. Real-world comparison of major bleeding risk among untreated non-valvular atrial fibrillation patients and those initiating apixaban, dabigatran, rivaroxaban, or warfarin. J Am Coll Cardiol. 2016;67(13):668.
   Web of Science ®Google Scholar
• Atzema CL, Dorian P, Fang J, et al. A clinical decision instrument to predict 30-day death and cardiovascular hospitalizations after an emergency department visit for atrial fibrillation: the atrial fibrillation in the emergency room, part 2 (AFTER2) study. Am Heart J. 2018;203:85–92.
   PubMed Web of Science ®Google Scholar
• Boggon R, Lip GYH, Gallagher AM, et al. Resource utilization and outcomes in patients with atrial fibrillation: a case control study. Appl Health Econ Health Policy. 2012;10(4):249–259.
   PubMedGoogle Scholar
• Boriani G, Diemberger I. Globalization of the epidemiologic, clinical, and financial burden of atrial fibrillation. Chest. 2012;142(6):1368–1370.
   PubMed Web of Science ®Google Scholar
• Hayden DT, Hannon N, Callaly E, et al. Rates and determinants of 5-year outcomes after atrial fibrillation–related stroke. Stroke. 2015;46(12):3488–3493.
   PubMed Web of Science ®Google Scholar
• Johansson C, Hägg L, Johansson L, et al. Characterization of patients with atrial fibrillation not treated with oral anticoagulants. Scand J Prim Health Care. 2014;32(4):226–231.
   PubMed Web of Science ®Google Scholar
• Kabra R, Girotra S, Vaughan Sarrazin M. Refining stroke prediction in atrial fibrillation patients by addition of African-American ethnicity to CHA 2 DS 2-VASc score. J Am Coll Cardiol. 2016;68(5):461–470.
   PubMed Web of Science ®Google Scholar
• Kim D, Yang P-S, Jang E, et al. Increasing trends in hospital care burden of atrial fibrillation in Korea, 2006 through 2015. Heart. 2018;104(24):2010–2017.
   PubMed Web of Science ®Google Scholar
• Kim YG, Choi J-I, Boo KY, et al. Impact of age on thromboembolic events in patients with non-valvular atrial fibrillation. Clin Cardiol. 2020;43(1):78–85.
   PubMed Web of Science ®Google Scholar
• Kloosterman M, Oldgren J, Conen D, et al. Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis. Europace. 2020;22(6):870–877.
   PubMed Web of Science ®Google Scholar
• Kotowycz MA, Filion KB, Joza J, et al. In-Hospital management of atrial fibrillation: the CHADS2 score predicts increased cost. Can J Cardiol. 2011;27(4):506–513.
   PubMed Web of Science ®Google Scholar
• Komatsu T, Tachibana H, Satoh Y, et al. Relationship between CHA2DS2-VASc scores and ischemic stroke/cardiovascular events in Japanese patients with paroxysmal atrial fibrillation without receiving anticoagulant therapy. J Cardiol. 2012;59(3):321–328.
   PubMed Web of Science ®Google Scholar
• Lin L-Y, Lee C-H, Yu C-C, et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation—a nation wide database analysis. Atherosclerosis. 2011;217(1):292–295.
   PubMed Web of Science ®Google Scholar
• Yu‐Sheng L, Tien‐Hsing C, Ching‐Chi C, et al. Different implications of heart failure, ischemic stroke, and mortality between nonvalvular atrial fibrillation and atrial flutter—a view from a national cohort study. J Am Heart Assoc. 2017;6(7):e006406.
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Dondi L, Andreotti F, et al. Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people. Am Heart J. 2020;220:12–19.
   PubMed Web of Science ®Google Scholar
• Mazurek M, Huisman MV, Rothman KJ, et al. Gender differences in antithrombotic treatment for newly diagnosed atrial fibrillation: the GLORIA-AF registry program. Am J Med. 2018;131(8):945–955.e3.
   PubMed Web of Science ®Google Scholar
• Ogilvie IM, Welner SA, Cowell W, et al. Characterization of the proportion of untreated and antiplatelet therapy treated patients with atrial fibrillation. Am J Cardiol. 2011;108(1):151–161.
   PubMed Web of Science ®Google Scholar
• Raji MA, Lowery M, Lin Y-L, et al. National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare part D beneficiaries. Ann Pharmacother. 2013;47(1):35–42.
   PubMed Web of Science ®Google Scholar
• Redfors B, Gray WA, Lee RJ, et al. Patients with atrial fibrillation who are not on anticoagulant treatment due to increased bleeding risk are common and have a high risk of stroke. JACC Clin Electrophysiol. 2017;3(12):1369–1376.
   PubMedGoogle Scholar
• Sakamoto Y, Okubo S, Nito C, et al. Insufficient warfarin therapy is associated with higher severity of stroke than no anticoagulation in patients with atrial fibrillation and acute Anterior-Circulation stroke. Circ J. 2018;82(5):1437–1442.
   PubMed Web of Science ®Google Scholar
• Song X, Sander SD, Johnson BH, et al. Impact of atrial fibrillation and oral anticoagulation on hospital costs and length of stay. Am J Health Syst Pharm. 2012;69(4):329–338.
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Kim S, Fonarow GC, et al. Drivers of hospitalization for patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF). Am Heart J. 2014;167(5):735–742.e2.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Yamashita T, Okumura K, et al. Incidence of ischemic stroke in Japanese patients with atrial fibrillation not receiving anticoagulation therapy-pooled analysis of the Shinken Database, J-RHYTHM Registry, and Fushimi AF Registry. Circ J. 2015;79(2):432–438.
   PubMed Web of Science ®Google Scholar
• Witassek F, Springer A, Adam L, et al. Health-related quality of life in patients with atrial fibrillation: the role of symptoms, comorbidities, and the type of atrial fibrillation. PLoS One. 2019;14(12):e0226730.
   PubMed Web of Science ®Google Scholar
• Corpataux N, Spirito A, Gragnano F, et al. Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. Eur Heart J. 2020;41(38):3743–3749.
   PubMed Web of Science ®Google Scholar
• Gragnano F, Calabrò P, Valgimigli M. Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention? Eur Heart J. 2019;40:216–217.
   PubMed Web of Science ®Google Scholar